Medtecs, listed in SGX, has TDR on Taiwan Stock Exchange.
The TDR is 1:1 with SG listed shares and closed at a high of TWD8.36 today.
TDR currently trades at equiv. of 39 SGD cents, while the SG-listed stock is trying hard to catch up but now at 26 cents.
Price run in Singapore has been accompanied by crazy volume : 110 M today, and 164 M, and 108 M in past 2 days.
The 2 prior days were even more crazy: 306 M and 393 M.
No query from SGX. What could it mean? Its surveillance system does not detect manipulation, just a hell of a lot of traders, retail investors, and speculators?
AGM on 19 June 2020: Should ask Qs to understand the scale of the business in YTD. So far, the management has been pretty busy with business / has been very low profile while the Covid has been driving lots of business.
>>>>>
Members who wish to ask questions relating to the resolutions to be tabled at the AGM must complete and submit the questions form for the AGM through the e-AGM Webcast Registration by clicking on the URL
smartagm.sg/
medtecsagm2020.
IF company reports USD8m net profit for Q2, I think 40 cent price target is achievable. Reason: EPS for 1st half year will be S$0.03c and PER will be 13x.
And we haven' t even factor in their profits for the second half year. If their Q3 and Q4 profits are as good as their Q2 of USD8m per quarter, EPS for 2020 will translate to S$0.07c.
At 10x PER, price would be $0.70c. But, please take this with a pinch of salt because these are just projections (but with a good chance that it is achievable). Good figure and DYODD.
post By 'investor8" at Sharejunction is pretty clear and good:
"The only problem I see is that the share price is not reflecting the " true" value of this stock in a " perfect" market situation. I can think of a few reasons why share price not trully reflecting value of company:
(1) Free-float too big
(2) Market being " controlled" by BBs
(3) No institutional interest because it is considered penny stock
(4) No market visibility and prominence because not covered by analysts
(5) Substantial shareholder (Chairman) not holding enough stock to " affect" share price
(6) Management cannot buy/sell the shares for fear of disrupting market (recall Xia Junwei).
"We are projecting company to post net profits ranging from at least USD16m to USD24m for whole year FY2020. Actual Q2 results will allow us to get a better forecast of whole year FY2020 since management had already said that H2 profits will be at least on par with H1. So if Q2 net profit is USD4.3m (which is only USD0.63m more than Q1 and more than likely to be achieved), then H2 profit will be at least USD8m which will hit the lowest estimate of USD16m. This translates to EPS of SGD0.041. If Q2 results are much better than expected, we can project a very very bullish figure of USD8.3m, then we hit USD24m for FY2020. Therefore Q2 results (to be announced in less than 2 months' time) very critical in getting a more accurate projection of whole year results. at USD24m for whole year, EPS would be SGD0.61. If we use a " reasonable" PER of 15x, share price should be in the range of S$0.60 to S$0.90. My two cents worth."
NextInsight
a hub for serious investors
